Top Markets
Coin of the day
Abivax S.A. Abivax S.A.

Abivax S.A.

ABVX
Classifica tra le azioni #2071
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013,... Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.
Prezzo delle azioni
$121.34
Capitalizzazione di mercato
$10.58B
Variazione (1 giorno)
4.28%
Variazione (1 anno)
59.66%
Paese
FR
Scambia Abivax S.A. (ABVX)

Categoria

Storico del prezzo dell'azione per Abivax S.A. (ABVX)
Prezzo di chiusura più alto: $124.86 il 2026-08-01

Prezzo di chiusura più basso: $23.10 il 2015-06-01
Storico del prezzo dell'azione di Abivax S.A. dal 2015 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -8.61%
2025 1,503.20%
2024 -26.43%
2023 60.28%
2022 -77.75%
2021 -2.30%
2020 54.91%
2019 56.94%
2018 22.67%
2017 47.19%
2016 -57.07%
2015 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$549.37 41.25%
US
$1.02K 51.15%
NL
$152.86 503.00%
US
$122.47 -12.71%
AU
$773.05 8.78%
CH